CSIMarket
 
Nkarta Inc   (NKTX)
Other Ticker:  
 
 
Price: $2.1700 $-0.17 -7.265%
Day's High: $2.35 Week Perf: 0.00
Day's Low: $ 2.16 30 Day Perf: -10.33 %
Volume (M): 636 52 Wk High: $ 16.24
Volume (M$): $ 1,379 52 Wk Avg: $5.89
Open: $2.34 52 Wk Low: $2.08



 Market Capitalization (Millions $) 160
 Shares Outstanding (Millions) 74
 Employees 119
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -111
 Cash Flow (TTM) (Millions $) 19
 Capital Exp. (TTM) (Millions $) 10

Nkarta Inc
Nkarta Inc is a biotechnology company founded in 2015, and headquartered in South San Francisco, California, in the United States of America. The company is focused on the development of genetically modified natural killer cells called NKT cells, that can be used for the treatment of cancer.

Nkarta's expertise lies in the development of CAR-NK cells, which are genetically engineered natural killer cells that are designed to recognize and attack cancer cells in the body. The company has developed a proprietary platform technology that enables the precise modification of NKT cells to improve their therapeutic potential. The technology involves the use of an antibody fragment, known as a single-chain variable fragment (scFv), which is linked to a signaling domain. This scFv recognizes a specific protein expressed on the surface of cancer cells, and upon binding, it activates the signaling domain to trigger a response from the NKT cells.

The approach is an alternative to CAR-T cell therapy, which uses genetically modified T cells to target cancer cells. The advantage of NKT cells is that they have a broader range of receptors than T cells, which means they can target a variety of cancer cells. Additionally, NKT cells are less likely to cause severe side effects, such as cytokine release syndrome, which is commonly observed with CAR-T cell therapy.

The company has a pipeline of CAR-NK cell therapies in development for the treatment of various cancers, including hematologic malignancies and solid tumors. In 2021, Nkarta received FDA clearance to initiate a clinical trial of its CAR-NK cell therapy targeting relapsed or refractory acute myeloid leukemia.

Nkarta has partnerships with several organizations, including CRISPR Therapeutics, which is providing gene editing technology, and the Leukemia & Lymphoma Society, which is funding the development of CAR-NK cell therapies.

In summary, Nkarta Inc is a biotechnology company that is revolutionizing cancer treatment by developing CAR-NK cell therapies. The company's genetically modified natural killer cells have the potential to target a wide range of cancers, with fewer side effects than traditional CAR-T cell therapy. With a robust pipeline and partnerships to support its growth, Nkarta is poised to make a significant impact in the fight against cancer.


   Company Address: 1150 Veterans Boulevard South San Francisco 94080 CA
   Company Phone Number: 407-1049   Stock Exchange / Ticker: NKTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -5.17%    
JNJ        0.82% 
LLY        8.38% 
MRK   -12.54%    
OGN   -1.95%    
REGN        6.47% 
• View Complete Report
   



Clinical Study

Augmenting Therapies Unleashing the Potential of NK Cells in Systemic Lupus Erythematosus and Acute Myeloid Leuk...

Published Wed, Jul 24 2024 10:00 AM UTC

Enhancing Treatment Options for Autoimmune and Hematologic Diseases: The Potential of NKX019 and NKX101 TherapiesThe field of immunotherapy has witnessed significant advancements in recent years, offering new hope for patients with autoimmune diseases and hematologic malignancies. One promising avenue of research involves the development of engineered natural killer (NK) cel...

Management Announcement

Nkarta Bolsters Leadership Team to Advance Pioneering NK Cell Therapies

Published Tue, Jul 16 2024 10:01 AM UTC

Nkarta Strengthens Leadership Team with New President and Chief Medical Officer
July 16, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a pioneering biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced significant changes to its leadership team. The company welcomes the appointment of Dr. Nadir Mahmood as President, who will share e...

Clinical Study

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis and Expands Pipeline to Address Autoimmune Indications

Published Thu, Jun 27 2024 10:00 AM UTC

In a groundbreaking development, Nkarta, a leading biopharmaceutical company, has recently commenced the clinical trial of their innovative engineered NK cell therapy, NKX019, for the treatment of lupus nephritis. Ntrust-1 marks the first U.S.-based clinical trial investigating the application of this therapy in lupus nephritis patients. This article aims to provide an overv...

Management Announcement

Nkarta's Underwritten Offering Amidst Financial Struggles Sparks Debate Over Future Growth Potential in Biopharmaceutical Sector

Published Mon, Mar 25 2024 10:30 AM UTC

Nkarta s Recent Underwritten Offering and Financial Performance Reflects Volatility in Biopharmaceutical Sector
SOUTH SAN FRANCISCO, Calif., March 25, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company specializing in the development of engineered natural killer (NK) cell therapies, recently announced the pricing of an underwritten offering, aiming to rais...

Clinical Study

An Innovative Leap: Nkarta?s Clinical Data on NKX101 Takes Center-Stage at the 2023 ASH Annual Meeting

Published Sun, Dec 10 2023 1:31 AM UTC


nnClinical Pioneers or Adventurers?nn,
San Francisco-based Nkarta, Inc., a company committed to creating pioneering treatments in the realm of cell therapies, has recently grabbed the spotlight at the American Society of Hematology (ASH) Annual Meeting and Exposition. Making significant strides in the clinical-stage biopharmaceutical industry, Nkarta, Inc. (Nasdaq:...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com